

## **How much will MYCAPSSA cost and will healthcare insurers provide coverage for patients?**

Chiasma believes MYCAPSSA will be viewed by payers as a significant innovation with important benefits for patients with acromegaly. Chiasma wants patients to have broad access to the innovation represented by MYCAPSSA at least on par with current long-acting SSA injectables. To accomplish this goal, the company plans to set the MYCAPSSA wholesale acquisition cost or list price at \$5,152 for a 28-day supply at the starting daily dose of 40 mg. The higher doses are linearly priced. By pricing MYCAPSSA competitively in this way, Chiasma believes it will deliver significant value with the first and only oral SSA for acromegaly patients facing challenges with injectables and that payers will reimburse for and provide broad access to MYCAPSSA.

As a reminder, this list price or WAC price is before any usual and customary adjustments and discounts and is sensitive to the mix of payers reimbursing for MYCAPSSA.

Now that MYCAPSSA is approved, Chiasma is continuing its dialogue with payers and expects many to put coverage policies in place over the coming months. During the interim timeframe, Chiasma plans to work closely with payers and providers to help patients obtain access to MYCAPSSA.

Dates: June 26, 2020